ClinicalTrials.gg
Active, not recruitingNCT06776432Updated May 6, 2026

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

A Phase 2 interventional study of Sivopixant and Placebo in Sleep Apnea, sponsored by Shionogi. Active, not recruiting at 9 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing acetazolamide in Sleep Apnea Syndromes — 2 open to participants now, 3 under way, none of them phase 3. Acetazolamide · Sleep Apnea Syndromes.

Enrollment
6th of 10
60 · median 76
Started
2025
the only one that year
Phase 2
3 of 11
none open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Shionogi

Among the 11 studies testing acetazolamide in Sleep Apnea Syndromes, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 11th registered.

Sleep Apnea Syndromes

1,084 studies on the registry are indexed under Sleep Apnea Syndromes; 171 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

2 of the 11 studies testing acetazolamide in Sleep Apnea Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About acetazolamide

Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Sleep Apnea Syndromes studies recruiting now, 57 (49%) set no upper age limit and 36 (31%) stop at 75 or younger; 24 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing acetazolamide in Sleep Apnea Syndromes, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the effectiveness of sivopixant, acetazolamide and SASS-001 in adults with sleep apnea with a central component.

03

Conditions studied

  • Sleep Apnea

Keywords

  • sleep apnea
  • obstructive sleep apnea
  • central sleep apnea
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To enroll, subjects need to have a previous diagnosis of at least one or more of the following comorbidities:

  • Stable heart failure with reduced ( class 1-3 inclusive) with or without atrial fibrillation
  • Heart failure with preserved ejection fraction (NYHA class 1-3 inclusive) and hypertension (BP>120/80 mmHg at screening visit despite the treatment with ≥2 antihypertensives) with or without atrial fibrillation
  • Persistent atrial fibrillation (continuous and sustained for more than 7 days, rate controlled with resting HR\<100bpm)1 without heart failure
  • History of primary (essential) hypertension with BP at screening visit >130/80 mmHg despite the treatment with >2 antihypertensives
  • Evidence of complex sleep apnea (CPAP-emergent central sleep apnea with documented CAI>5 events/h on CPAP within 1 year from screening)

Standard care for heart failure and atrial fibrillation for at least 3 weeks before the screening visit

OSA measures Average ODI4 between 7 and 55 events/h, inclusive, and average SpO2 ≥88% from continuous home pulse oximetry recordings at screening.

AHI4 (Hypopneas defined by 4% oxygen desaturation) of >10 to ≤60 events/h

  1. At minimum of 25% central or mixed apneas (as proportion of total apneas) with a minimum of 2.5 central or mixed apneas/hour of sleep
  2. OR evidence of clear Cheyne-Stokes breathing pattern during the baseline PSG (regardless of central apnea component).
  3. OR evidence of OSA with LGn >0.5 at the baseline PSG (regardless of central apnea component) Average SpO2 during sleep ≥88%

Weight between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive

Male participants If male and sexually active with female partner(s) of , participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified . Male participants must refrain from donating sperm for the duration of the study and for 3 months after the last dose of study treatment.

Female participants If a woman of childbearing potential (WOCBP), the participant must agree, from Study Day 1 through 1 week after the last dose of study drug, to practice the protocol specified contraception. All WOCBP must have negative result of a serum pregnancy test performed at screening.

If female and of non-childbearing potential, the participant must be either or permanently sterile (e.g. bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

Participant voluntarily agrees to participate in this study and signs an Institutional Review Board (IRB)-approved informed consent prior to performing any of the Screening Visit procedures.

Participant must be able to understand the nature of the study and must have the opportunity to have any questions answered.

Patients currently using PAP will be eligible for inclusion in the study if they express willingness to discontinue treatment for a minimum of 7 days before baseline SpO2 assessments, until the study completion.

Exclusion criteria

Exclusion criteria Vital signs and symptoms

Sustained SpO2\<93% during wakefulness or mean SpO2\<88% during sleep, calculated from PSG at screening

Dyspnea at rest or patients with heart failure class IV

Blood pressure \<90/50 mmHg or >160/100 mmHg at V1.

Medical Conditions Recent (\<3 months) episode of acute myocardial infarction or acute decompensated heart failure.

History of stroke.

History of sustained ventricular tachyarrhythmias or other severe arrhythmias without defibrillator implanted.

Heart failure primarily caused by valvular, post-partum cardiomyopathy or active myocarditis

History of obesity-hypoventilation syndrome or respiratory disturbance due to opioids.

History of bronchiectasis and uncontrolled asthma.

History of severe (COPD) with a (FEV1) \<50% of predicted (European Respiratory Society criteria)

Started treatment with β-blockers \<3 months before screening. Patients not taking β-blockers or taking β-blockers for >3 months can be enrolled.

Narcolepsy, restless leg syndrome requiring medication, REM sleep behavior disorder.

Pronounced anatomical abnormalities of upper airway (adenoid vegetations, grade ≥3 tonsillar hypertrophy, etc.), pronounced micrognathia, or pronounced incomplete development of the lower jaw.

History of schizophrenia, schizoaffective disorder or bipolar disorder according to -5 (DSM-5) or International Classification of Disease tenth edition criteria.

Medically unexplained positive screen for drugs of abuse (excluding THC/marijuana) or history of substance use disorder as defined in DSM-V within 24 months prior to Screening Visit.

A significant illness or infection requiring medical treatment in the past 30 days as determined by investigator.

cognitive dysfunction as determined by investigator.

Women who are pregnant or nursing.

History of kidney stones

Prior/Concomitant Therapy Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 1 week before the baseline SpO2 assessments and are not used during participation in the study (through V7). Patients that are non-compliant to CPAP (less than 4hr/night for 5 days/week) can be enrolled, as well as patients who are naïve to PAP and patients who discontinued PAP previously. PAP compliant patients cannot be enrolled.

History of chronic oxygen therapy.

Concomitant use of medications from the list of disallowed medications.

Prior/Concurrent Clinical Study Experience Use of another agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.

Diagnostic Assessments Hepatic cirrhosis, hepatictransaminases > 2X the (ULN), total >1.5X ULN (unless confirmed Gilbert syndrome), estimated \< 40 ml/min.

Participants with reduced sodium and/or potassium blood serum levels.

Participants with suprarenal gland failure.

Participants with hyperchloremic acidosis.

Other Exclusions:

Night- or shift-work sleep schedule which causes the major sleep period to be during the day.

Employment as a commercial driver or operator of heavy or hazardous equipment.

Typically smoking more than 10 cigarettes or 2 cigars per day, or inability to abstain from smoking during overnight PSG visits.

Unwilling to use specified .

History of regular alcohol consumption of more than 14 standard units per week (males) or more than 7 standard units per week (females), or unwillingness to limit alcohol consumption to no greater than 2 units/day (males), 1 unit per day (females). Alcohol is not to be consumed within 3 hours of bedtime or on PSG nights.

Unwilling to agree to limit during the study period caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day or less of caffeine, not to be used within 3 hours of bedtime.

Any condition that in the investigator's opinion would present an unreasonable risk to the participant, including recent (\<1 year) motor vehicle accident due to drowsy driving, or which would interfere with their participation in the study or confound study interpretation.

Participant considered by the investigator, for any reason, an unsuitable candidate to receive sivopixant or acetazolamide or unable or unlikely to understand or comply with the dosing schedule or study evaluations.

Allergy to study drugs

  • Note: Other protocol defined Inclusion/Exclusion criteria may apply
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Part A: Sivopixant

    Participants will receive sivopixant oral tablets once daily at bedtime for 17 days.

    Drug: Sivopixant

  • Placebo comparator
    Placebo

    Participants will receive placebo to match the study drug during the 17 days of Part A followed by 13 days of Part B.

    Drug: Placebo

  • Active comparator
    Part B I: Acetazolamide

    After completing Part A, participants will receive acetazolamide oral tablets once daily at bedtime for 3 days.

    Drug: Acetazolamide

  • Active comparator
    Part B II: SASS-001

    After completing Part B I, participants will receive SASS-001 oral tablets once daily at bedtime for 10 days.

    Drug: SASS-001

Interventions

  • DrugSivopixant

    Administered as specified in the treatment arm

  • DrugPlacebo

    Administered as specified in the treatment arm.

  • Administered as specified in the treatment arm

  • DrugSASS-001

    Administered as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Primary Endpoint - Change in apnea-hypopnea index (SASS-001 arm vs baseline at Visit 7 polysomnography). Scale is minimum -60 to max 60. Lower scores mean improvement from baseline.

    Time frame: up to 6 weeks

Secondary outcomes

  1. Secondary Endpoint - Change in apnea-hypopnea index (Sivopixant alone vs baseline at Visit 5 polysomnography). Scale is minimum -60 to max 60. Lower scores mean improvement from baseline.

    Time frame: up to 6 weeks

Other outcomes

  1. Additional Secondary Endpoint: Change in apnea-hypopnea index (SASS-001 vs Acetazolamide alone - visit 7 vs visit 6 polysomnography). Scale is minimum -60 to max 60. Lower scores mean improvement from baseline.

    Time frame: Two weeks

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 17 phase 2 interventional studies under Sleep Apnea Syndromes, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 15, 2025
StartActual
Apr 2, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06776432
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Apr 2, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Chief Scientific Officer
study director · Apnimed

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetazolamide

Start the discussion